Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France

Inclusion Criteria:

• Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucosesensor (any model) for at least 14 days prior to the date of installation of themylife YpsoPump, with at least 70% coverage, under the same sensor.

• Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FXhybrid closed loop.

• Patient who received the information sheets and gave their consent to participate inthe study and to the processing of their personal data.

• Adult patient who signed an informed consent form to participate in the study orminor patient whose parents signed an informed consent form for their child'sparticipation in the study.

• Adult patient, minor patient old enough to complete the questionnaires or parent ofa minor patient able to read and understand French.

• Adult patient / minor patient capable to complete the questionnaires or parent of aminor patient who agrees to complete the online self-questionnaires.

Exclusion Criteria:

• Patient who used a hybrid closed-loop system, a fully closed-loop system, or ado-it-yourself loop system, regardless of the brand or model, within the past 6months.

• Patients participating or having participated in a clinical trial in the previousmonth that prevents them from participating in other studies.

• Patient or parent unable to give consent.

• Protected Patient (subject to a legal protection measure: guardianship, curatorshipor legal safeguard).

• Patient with a contraindication to the prescription of the mylife CamAPS FX hybridclosed-loop ( according to the Instructions For Use, IFU).

• Patient with an unresolved skin condition in the area of sensor placement and/or inthe tubing placement area (e.g. psoriasis, dermatitis herpetiformis, rash,staphylococcal infection).

• Patient with unstable diabetic retinopathy requiring laser treatment.

• Patient with a concomitant condition or treatment that alters glucose metabolism andthat, in the investigator's judgment, is likely to have a significant impact onglycemic control;

• Patient whose follow-up cannot be carried out by the centre (relocation plannedwithin 12 months of inclusion).